Clinical observation of temozolomide and fotemustine in treating patients with malignant gliomas

WU Xinhu,ZHU Xixu,SHEN Zetian,LI Bing,SHEN Junshu,GAO Shuping
DOI: https://doi.org/10.3969/j.issn.1672-4992.2012.06.21
2012-01-01
Journal of Modern Oncology
Abstract:Objective:To compare the therapeutic effect,survival and safety of malignant gliomas patients treated with temozolomide(TMZ) and fotemustine.Methods: A total of 56 postoperative patients with malignant glioma were randomly divided into two groups: TMZ treatment and Fotemustine treatment group.All patients were performed conventional radiotherapy,2Gy/d,5d/W,6-7weeks as a treatment course,for a total of 60-66Gy.The patients of TMZ group were given daily oral temozolomide 75mg/m2 during radiotherapy.4 weeks after radiotherapy,all of the patients received 4-6 cycles of Temozolomide(150-200)mg/m2.The fotemustine group received fotemustine 100mg/m2 every week during the radiotherapy for 3 weeks.Then followed after a 5-week rest period by fotemustine 100mg/m2 every 3 weeks for 4-6 cycles.Results: The overall response rates(CR+PR) of the TMZ group and control group separately were 78.6% and 50%,there was significant difference between the two groups(P<0.05).The 1,2 and 3 year survival rates of patients in the TMZ group were 71.4%,39.3%,28.6%,and 57.1%,32.1%,17.9% in Fotemustine group.The median recurrent period in the TMZ group were 22 and 12 months in control group,and also with no singnificant difference(P=0.013).The happening rate of vomitting and myelotoxicity in TMZ group was lower than that in Fotemustine group(P<0.001).But the acute and late toxicity of brain was similar in 2 groups(P>0.05).Conclusion: TMZ can improve the local control rate and maybe hopeful to prolong the survival rate with less side effect compared to Fotemustine in patients with malignant gliomas.
What problem does this paper attempt to address?